A company developing new therapeutic options for Parkinson’s disease and Epilepsy, PixarBio Corporation signed a five-year lease agreement for their new corporate headquarters and research center at 200 Boston Avenue in Medford, Massachusetts
. At just under 8,000 sq. ft., the facility will house state-of-the-art Chemical, Bio
, and Tissue labs. The company will also move its corporate headquarters to the Medford facility.
Located in close proximity to its innovation roots at Harvard and MIT, PixarBio Corp. said it will have capacity to quickly expand beyond biomaterials needed for Parkinson’s disease to include biomaterials for Epilepsy.
“We are building a home for our world renowned and award winning team of researchers to drive innovation and accelerate the development of new treatment options for Parkinson’s disease. We’re confident that our optimized R&D model will generate key intellectual property permitting PixarBio to lead the development of next generation biomaterials for the treatment of Parkinson’s disease as well as a range of chronic neurological conditions,” says CTO Randy Holmes-Farley, PhD.
Frank Reynolds, PixarBio’s CEO adds, “We’ll move to Medford, MA in early 2014 and get to work on achieving our objective of rapidly bringing a new Parkinson’s treatment to market. Along the way we’ll explore M&A in the biomaterials space while focusing on expanding our platform.”